Literature DB >> 9302

Gastrointestinal absorption and metabolism of two 35S-labelled ampicillin esters.

A Swahn.   

Abstract

Two ampicillin esters, 35S-pivampicillin and 35S-carampicillin and polyethylene glycol (nonabsorbable marker) were given orally to healthy subjects with gastrointestinal tubes. The cumulative absorption of radioactivity in both compounds (60-90%) was higher than (25-67%) previously found after administration of 35S-ampicillin. The pek plasma levels of radioactivity were reached earlier and were about twice as high as in the latter study. The amount of radioactivity excreted in urine was about the same as that absorbed from the proximal part of the gastrointestinal tract. Both 35S-pivampicillin and 35S-carampicillin were partly hydrolyzed in the stomach and upper small intestine and labelled ampicillin was released. They were also decomposed after absorption since all the radioactivity recovered from blood and urine appeared to be attached to ampicillin and ampicillin metabolites. Studies in vitro indicated that ampicillin esters absorbed intact may be hydrolyzed not only in the blood but also in the intestinal wall and the liver.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9302     DOI: 10.1007/BF00561664

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Pivampicillin: a preliminary report of its pharmacokinetic properties and therapeutic efficacy.

Authors:  J B Wilcox; R N Brogden; G S Avery
Journal:  Drugs       Date:  1973       Impact factor: 9.546

2.  Fate of oral 35S-cloxacillin in man.

Authors:  K Hellström; A Rosén; A Swahn
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

Review 3.  Recent contributions in intestinal absorption and malabsorption. A review.

Authors:  M H Floch
Journal:  Am J Clin Nutr       Date:  1969-03       Impact factor: 7.045

4.  Chromatographic assay of mixed penicillins, ampicillin and cloxacillin in body fluids.

Authors:  T Murakawa; Y Waki; M Nishida; R Fuji; M Konno
Journal:  J Antibiot (Tokyo)       Date:  1970-05       Impact factor: 2.649

5.  Cefazolin, a new semisynthetic cephalosporin antibiotic. 3. Absorption, excretion and tissue distribution in parenteral administration.

Authors:  M Nishida; T Matsubara; T Murakawa; Y Mine; Y Yokota; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1970-04       Impact factor: 2.649

Review 6.  Marker perfusion techniques for measuring intestinal absorption in man.

Authors:  J S Fordtran
Journal:  Gastroenterology       Date:  1966-12       Impact factor: 22.682

7.  The gastrointestinal absorption and the excretion of H3-butylscopolamine (hyoscine butylbromide) in man.

Authors:  K Hellström; A Rosén; K Söderlund
Journal:  Scand J Gastroenterol       Date:  1970       Impact factor: 2.423

8.  Pivampicillin, a new orally active ampicillin ester.

Authors:  W von Daehne; W O Godtfredsen; K Roholt; L Tybring
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

9.  Absorption and decomposition of potassium-35S-phenoxymethyl penicillin.

Authors:  K Hellström; A Rosén; A Swahn
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

10.  On the absorption and metabolism of 35S-ampicillin.

Authors:  A Swahn
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

  10 in total
  10 in total

1.  Potential improvement in the shelf life of parenterals using the prodrug approach: bacampicillin and talampicillin hydrolysis kinetics and utilization time.

Authors:  N A Nguyen; L M Mortada; R E Notari
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

2.  A clinical evaluation of the tolerance to pivampicillin tablets.

Authors:  H Hey; T J Medalen; O M Molstad; K Stokholm
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.

Authors:  D K Sommers; M van Wyk; J Moncrieff; H S Schoeman
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

Review 4.  Pharmacokinetics of bacampicillin tablets in adults.

Authors:  W A Craig
Journal:  Bull N Y Acad Med       Date:  1983-06

5.  A gastroscopic and pharmacological study of the disintegration time and absorption of pivampicillin capsules and tablets.

Authors:  H Hey; P Matzen; J T Andersen; E Didriksen; B Nielsen
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

6.  Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam.

Authors:  T J Carty; A Marfat; P F Moore; F C Falkner; T M Twomey; A Weissman
Journal:  Agents Actions       Date:  1993-07

7.  Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin.

Authors:  L Magni; J Sjövall; E Syvälahti
Journal:  Infection       Date:  1978       Impact factor: 3.553

8.  A double-blind comparison of the clinical tolerance of bacampicillin and pivampicillin. A preliminary report.

Authors:  A Koldestam; S Olsson; L Berglund
Journal:  Infection       Date:  1979       Impact factor: 3.553

9.  Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.

Authors:  M Ehrnebo; S O Nilsson; L O Boréus
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

10.  Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.

Authors:  C A McNulty; J C Dent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.